Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.
@article{Eichhorn2008Phosphatidylinositol3H, title={Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.}, author={Pieter Johan Adam Eichhorn and Mag{\"u}i Gili and Maurizio Scaltriti and Violeta Serra and Marta Guzm{\'a}n and Wouter Nijkamp and Roderick L. Beijersbergen and Vanesa Valero and Joan Seoane and Ren{\'e} Bernards and Jos{\'e} Baselga}, journal={Cancer research}, year={2008}, volume={68 22}, pages={ 9221-30 } }
Small molecule inhibitors of HER2 are clinically active in women with advanced HER2-positive breast cancer who have progressed on trastuzumab treatment. However, the effectiveness of this class of agents is limited by either primary resistance or acquired resistance. Using an unbiased genetic approach, we performed a genome wide loss-of-function short hairpin RNA screen to identify novel modulators of resistance to lapatinib, a recently approved anti-HER2 tyrosine kinase inhibitor. Here, we… CONTINUE READING
Citations
Publications citing this paper.
SHOWING 1-10 OF 271 CITATIONS, ESTIMATED 51% COVERAGE
Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED
The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED
PRKACA Mediates Resistance to HER2-Targeted Therapy in Breast Cancer Cells and Restores Anti-Apoptotic Signaling
VIEW 4 EXCERPTS
HIGHLY INFLUENCED
Current approaches and future directions in the treatment of HER2-positive breast cancer.
VIEW 4 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells
VIEW 8 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED
Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer.
VIEW 11 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED
Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.
VIEW 8 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED
Phosphorylated HER3 and FITC-labeled trastuzumab immunohistochemistry in patients with HER2-positive breast cancer treated with adjuvant trastuzumab
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED
Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies.
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED
Use of genetically engineered mouse models in preclinical drug development
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED
FILTER CITATIONS BY YEAR
CITATION STATISTICS
19 Highly Influenced Citations
Averaged 15 Citations per year from 2017 through 2019
References
Publications referenced by this paper.
SHOWING 1-10 OF 43 REFERENCES
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL